--- canonical_url: https://www.stockexpertai.com/earnings/regn last_updated: 2026-05-05T20:01:55.573Z --- # Regeneron Pharmaceuticals, Inc. (REGN) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-05T20:01:55.283Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $702.33 (▼ -0.97%) | fmp:quote | | Market Cap | $72.4B | fmp:profile | | 52w range | $476.49 – $821.11 | fmp:quote | | Earnings | Thu 30 Jul | fmp:earnings-history | | EPS estimate | $10.88 (-16% YoY) | fmp:earnings-estimate | | Revenue estimate | $3.8B | fmp:earnings-estimate | | Beat streak | 4/4 | fmp:earnings-history | | Rating | A (overall 4/5) | fmp:ratings | | Analyst median target | $873 (+24.3% upside) | fmp:price-target-consensus | | MoonshotScore | 50/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Regeneron Pharmaceuticals, Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $3.8B^{[FMP est]}, EPS $10.88^{[FMP est]}. 4 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** A · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 50 = MoonshotScore 50^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (4 metrics) ### 1. Dupixent Growth DUPIXENT global net sales increased 31% on a constant currency basis to $4.9 billion in the quarter, reinforcing its position as the foundation of our immunology franchise. > "Global DUPIXENT net sales increased 31% on a constant currency basis to $4.9 billion in the quarter." > — Leonard Schleifer, CEO, Investor Focus · Q1 FY2026 ### 2. Eylea Hd Growth EYLEA HD U.S. net product sales increased 52% year-over-year to $468 million, reflecting confidence in its clinical profile and dosing flexibility. > "EYLEA HD U.S. net product sales increased 52% year-over-year to $468 million." > — Leonard Schleifer, CEO, Investor Focus · Q1 FY2026 ### 3. Share Repurchase Program Regeneron's Board authorized a new $3 billion share repurchase program, reflecting confidence in our business and financial position. > "In support of that approach our Board authorized a new $3 billion share repurchase program, reflecting confidence in our business and financial position." > — Leonard Schleifer, CEO, Investor Focus · Q1 FY2026 ### 4. Otarmeni Free Access Regeneron decided to make Otarmeni free in the United States because they believe it was the right thing to do for these families. > "We decided to make Otarmeni free in the United States because we believe it was the right thing to do for these families." > — George Yancopoulos, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-1.9%, contraction) | | Gross Margin | 8.0 | strong | Q1: very high margin (81.4%, software/cloud territory) | | Operating Leverage | 2.0 | weak | op margin healthy (17.8%) | | Cash Runway | 10.0 | strong | FCF very strong ($0.8B, 3.7× CapEx) | | R&D Intensity | 3.0 | weak | very high R&D (42.0%, margin pressure risk) | | Price Momentum | 4.0 | medium | RSI 37.9 weak momentum, 50d below | | News Sentiment | 8.0 | strong | strong buy consensus (76%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +24.3% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 38 | | Klarman | neutral | value · target upside +24.3% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +24.3% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Strong - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 37.9 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $752 — hisse %6.7 altında — kısa vadeli direnç - **200d MA:** $685 — hisse %2.5 üstünde — uzun vadeli destek - **Volume (10d):** -82% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $12.89 | $8.43 | BEAT | +2.3% | | Q3 FY25 | $11.83 | $9.65 | BEAT | -0.2% | | Q4 FY25 | $11.44 | $10.74 | BEAT | +1.8% | | Q1 FY26 | $9.47 | $8.91 | +6.3% EPS | +3.0% | Q1 (April 29, 2026): EPS $9.47 vs $8.91 est^[FMP], +6.3% beat. D+1 movement: +3.0%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $10.88 + CapEx discipline** Threshold: EPS > $10.88^{[FMP est]}. Target: Break above median target $873^{[FMP target]}; high target $1057^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $10.88 + CapEx < $230.6M** Threshold: EPS ≈ $10.88^{[FMP est]}, Q4 CapEx < $230.6M^[FMP]. Target: Consolidation in the band between current $702^[FMP] and median $873^[FMP]. ### Scenario C · Miss **EPS < $10.55 or CapEx ≥ $230.6M** Threshold: EPS < $10.55^{[FMP est×0.97]}. Target: Current $702 below SMA200 $685^[FMP], if rejection continues, $582^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $9.47 vs $8.91 beat^[FMP], stock +3.0% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $230.6M^{[FMP cashflow]}. Q1 op margin 17.8%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $873 (+24.3% upside vs current $702) - **High / Low:** $1057 / $700 - **Buy / Hold / Sell:** 22 / 7 / 0 - **Analyst count:** 11 (last quarter), 122 all-time ## Additional Transcript Insights ### 1. dupixent_growth **Claim:** DUPIXENT global net sales increased 31% on a constant currency basis to $4.9 billion in the quarter, reinforcing its position as the foundation of our immunology franchise. **Evidence (transcript):** "Global DUPIXENT net sales increased 31% on a constant currency basis to $4.9 billion in the quarter." **Numbers:** 31%, $4.9 ### 2. eylea_hd_growth **Claim:** EYLEA HD U.S. net product sales increased 52% year-over-year to $468 million, reflecting confidence in its clinical profile and dosing flexibility. **Evidence (transcript):** "EYLEA HD U.S. net product sales increased 52% year-over-year to $468 million." **Numbers:** 52%, $468 ### 3. otarmeni_free_access **Claim:** Regeneron decided to make Otarmeni free in the United States because they believe it was the right thing to do for these families. **Evidence (transcript):** "We decided to make Otarmeni free in the United States because we believe it was the right thing to do for these families." **Numbers:** — ### 4. share_repurchase_program **Claim:** Regeneron's Board authorized a new $3 billion share repurchase program, reflecting confidence in our business and financial position. **Evidence (transcript):** "In support of that approach our Board authorized a new $3 billion share repurchase program, reflecting confidence in our business and financial position." **Numbers:** $3 --- *Data source: FMP (live query, 2026-05-05), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*